Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News Archive
News Archive Navigation
icon
News Archive Navigation Language
Language Preferences
Showing 1843 results
March 2018
-
Media Release
Novartis to present predictability data for brolucizumab in nAMD from pivotal HAWK and HARRIER trials at ARVO
Basel, March 28, 2018 - Novartis will present new data from the HAWK and HARRIER Phase III trials at the upcoming Association for Research in Vision and Ophthalmology (ARVO) 2018 Annual Meeting,… -
Media Release
AveXis Gene Therapy Awarded SAKIGAKE Designation for Spinal Muscular Atrophy Type 1
CHICAGO, March 27, 2018 (GLOBE NEWSWIRE) -- AveXis, Inc. (NASDAQ:AVXS), a clinical-stage gene therapy company developing treatments for patients suffering from rare and life-threatening… -
Key Release
Novartis verkauft Beteiligung an Consumer-Healthcare-Joint-Venture für USD 13 Milliarden an GSK, um sich auf strategische Prioritäten zu konzentrieren
Preis stellt für Novartis einen attraktiven Wert dar Verkaufserlös wird in Übereinstimmung mit den Prioritäten für die Kapitalallokation verwendet, einschliesslich für Bolt-on-Akquisitionen Verkauf… -
Key Release
Novartis to sell stake in consumer healthcare joint venture to GSK for USD13.0 billion to focus on strategic priorities
Price reflects an attractive value to Novartis Proceeds to be used according to capital allocation priorities, including bolt-on acquisitions Sale of JV in a non-core segment in best long-term… -
Media Release
Sandoz receives positive CHMP opinion for proposed biosimilar infliximab
Sandoz is seeking approval of biosimilar infliximab for use in all indications of its reference medicine across gastroenterology, rheumatology and dermatology Positive opinion is based on a… -
Malaria is still disrupting lives, despite progress
The disease hobbles families and economies.
-
Media Release
Phase III data in The Lancet show Novartis siponimod significantly improves outcomes in patients with secondary progressive MS
EXPAND shows oral siponimod (BAF312) is the first potential therapy to meaningfully delay disability progression in typical secondary progressive MS (SPMS) patients Results demonstrate… -
Media Release
Novartis drug Tasigna® approved by FDA to treat children with rare form of leukemia
Tasigna® (nilotinib) approved for pediatric patients with newly diagnosed Ph+ CML-CP and children with Ph+ CML-CP resistant or intolerant to prior TKI therapy New indication approved under FDA… -
Building “boot camps” for immune cells near tumors
Bioengineers, immunologists and clinicians collaborate to explore a new approach to fighting cancer.
-
Media Release
Novartis teams up with Harvard to develop next generation biomaterial systems to deliver immunotherapies
Collaboration and licensing agreement combine Harvard's expertise in tumor biology and materials science with Novartis' diverse immuno-oncology pipeline Teams will explore the development… -
Featured News
Novartis Foundation joins Global Partnership for Zero Leprosy
Leprosy is an ancient disease that currently infects more than 200 000 people each year. For more than three decades, Novartis and the Novartis Foundation has been working to reduce the incidence of leprosy, and the Novartis Foundation recently helped establish the Global Partnership for Zero Leprosy in an effort to eliminate the disease.
-
Media Release
AveXis Enters into Licensing Agreement with Genethon
Includes exclusive worldwide rights to AAV9-SMN product and route of administration CHICAGO and ÉVRY, France, March 13, 2018 (GLOBE NEWSWIRE) -- AveXis, Inc. (NASDAQ:AVXS) and Genethon today…
Pagination
- ‹ Previous page
- 1
- …
- 94
- 95
- 96
- 97
- 98
- 99
- 100
- …
- 154
- › Next page
Test disclaimer...!!!